Zevra Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Zevra Therapeutics generated cash of -$33,534,999, which is less than the previous year. Cash used in financing activities reached the amount of $28,464,000 last year. Net change in cash is therefore -$22,416,999.
Cash Flow
| 2014 | -14.67M | -43.72K | 23.00M |
|---|---|---|---|
| 2015 | -20.26M | -19.13M | 61.46M |
| 2016 | -29.77M | -46.94M | 61.16M |
| 2017 | -33.1M | 27.41M | -203K |
| 2018 | -54.20M | 33.33M | 28.01M |
| 2019 | -23.73M | 3.23M | 4.93M |
| 2020 | -1.93M | -33K | 2.73M |
| 2021 | 10.43M | -15.52M | 113.10M |
| 2022 | -18.71M | -36.71M | 8.35M |
| 2023 | -33.53M | -17.39M | 28.46M |
ZVRA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 65.46M | 112.34M | 4.32M | 3.55M | 19.11M | 11.97M | 17.86M | 32.31M | 10.25M | 1.96M |
Operating activities | ||||||||||
Net income | -46.04M | -41.54M | -8.55M | -12.76M | -24.52M | -56.46M | -43.38M | -16.51M | -54.66M | -24.45M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.00M | 944K | 257K | 273K | 304K | 324K | 336K | 175K | 84K | 74.76K |
Stock-based compensation expense | 5.95M | 4.29M | 2.43M | 2.49M | 4.41M | 0 | 4.56M | 6.6M | 2.36M | 213.75K |
| Deferred income tax benefit | 5.95M | 4.29M | 2.43M | 2.49M | 4.41M | 0 | 4.56M | 6.6M | 2.36M | 213.75K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -9.07M | -6.77M | 1.05M | -714K | -1.72M | 0 | 0 | 0 | 0 | 0 |
Inventories | 206K | 147K | 0 | -217K | 5.51M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 11.13M | 3.13M | -1.11M | 931K | -3.78M | 0 | -801K | 0 | 0 | 0 |
Cash generated by operating activities | -33.53M | -18.71M | 10.43M | -1.93M | -23.73M | -54.20M | -33.1M | -29.77M | -20.26M | -14.67M |
Investing activities | ||||||||||
Purchases Of Investments | -45.81M | -22.53M | -15.42M | 0 | 0 | 0 | -27.37M | -89.84M | -19.00M | 0 |
Investments In Property Plant And Equipment | -296K | -93K | -102K | -33K | -26K | -21K | -181K | -643K | -135K | -48.72K |
Acquisitions Net | -30.40M | -14.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -17.39M | -36.71M | -15.52M | -33K | 3.23M | 33.33M | 27.41M | -46.94M | -19.13M | -43.72K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 86.03M | 2.30M | 0 | 28.32M | 4K | 0 | 59.89M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -3.44M | -4.72M | -2.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 25.58M | 12.78M | -38.09M | -227K | 5.23M | -193K | -157K | -20.63M | 3.96M | -66.14K |
Cash used in financing activities | 28.46M | 8.35M | 113.10M | 2.73M | 4.93M | 28.01M | -203K | 61.16M | 61.46M | 23.00M |
Net Change In Cash | -22.41M | -46.88M | 108.02M | 767K | -15.56M | 7.14M | -5.89M | -15.55M | 22.06M | 8.28M |
Cash at end of period | 43.04M | 65.46M | 112.34M | 4.32M | 3.55M | 19.11M | 11.97M | 16.76M | 32.31M | 10.25M |
| Data source |